Dvorak C C, Cowan M J
Department of Pediatrics, UCSF Children's Hospital, San Francisco, CA 94143-1278, USA.
Bone Marrow Transplant. 2008 Jan;41(2):119-26. doi: 10.1038/sj.bmt.1705890. Epub 2007 Oct 29.
Hematopoietic stem cell transplantation is the definitive therapy for a variety of rare primary cellular immunodeficiency syndromes diagnosed in children. All primary immunodeficiencies benefit from early diagnosis and transplantation before the development of serious infections, which contribute to a significant increased risk of mortality following transplant. In the absence of a matched sibling, parental haplocompatible, matched unrelated donor and cord blood stem cells have all been utilized with varying degrees of success and immune reconstitution. The role of pretransplant conditioning in patients with SCID disease in terms of its effects upon T- and B-cell immune reconstitution and late effects is still under debate and will require further study.
造血干细胞移植是治疗儿童诊断出的多种罕见原发性细胞免疫缺陷综合征的决定性疗法。所有原发性免疫缺陷在严重感染发生之前进行早期诊断和移植均有益处,严重感染会显著增加移植后死亡风险。在没有匹配同胞供者的情况下,父母单倍型相合供者、匹配的无关供者以及脐血干细胞均已被不同程度地成功应用于免疫重建。移植前预处理对重症联合免疫缺陷病(SCID)患者T细胞和B细胞免疫重建的影响及其远期效应仍存在争议,需要进一步研究。